Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 8/20 | 1.00 |
| ▸ | GABRP | O00591 | 5/20 | 1.00 |
| ▸ | GABRD | O14764 | 5/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 5/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 5/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 5/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 5/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 5/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 5/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 5/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 5/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 5/20 | 1.00 |
| ▸ | GABRE | P78334 | 5/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 5/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 5/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 1.00 |
| ▸ | PARP1 | P09874 | 3/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 1.00 |
| ▸ | GUSB | P08236 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23070093 | 0.86 | TNKS (0.93) | TNKSGABRPGABRDGABRA1GABRB1 | |
| Flavone SCHEMBL15676601 | 0.86 | TNKS (1.00) | TNKSGABRPGABRDGABRA1GABRB1 | |
| Flavone SCHEMBL28248986 | 0.86 | TNKS (1.00) | TNKSGABRPGABRDGABRA1GABRB1 | |
| Flavone SCHEMBL31316377 | 0.86 | TNKS (1.00) | TNKSGABRPGABRDGABRA1GABRB1 | |
| Flavone SCHEMBL18879 | 0.86 | TNKS (1.00) | TNKSGABRPGABRDGABRA1GABRB1 | |
| Flavone SCHEMBL30542161 | 0.86 | TNKS (1.00) | TNKSGABRPGABRDGABRA1GABRB1 | |
| Flavone SCHEMBL9530678 | 0.84 | TNKS (0.96) | TNKSGABRPGABRDGABRA1GABRB1 | |
| Flavone SCHEMBL6908621 | 0.84 | TNKS (0.96) | TNKSGABRPGABRDGABRA1GABRB1 | |
| Flavone SCHEMBL1660769 | 0.84 | TNKS (0.96) | TNKSGABRPGABRDGABRA1GABRB1 | |
| Flavone SCHEMBL8069086 | 0.84 | TNKS (0.96) | TNKSGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8436031-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436031-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006076009-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1558341-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050124678-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1524974-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004041209-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004001058-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030229065-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-6046231-A | ADMINISTERING A SUFFICIENT AMOUNT OF A CANCER CHEMOPREVENTATIVE COMPOSITION COMPRISING 4'-BROMOFLAVONE TO A MAMMAL IN NEED TO PREVENT, DELAY OR REVERSE A CANCER SENSITIVE TO 4'-BROMOFLAVONE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0267155-A2 | Bicyclic compounds | Zyma SA (CH) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | TNKS 1140/4885GABRP 1579/4885GABRD 1267/4885 |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | TNKS 1140/4885GABRP 1579/4885GABRD 1267/4885 |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JUN, CREBBP, TFEB | TNKS 1140/4885GABRP 1579/4885GABRD 1267/4885 |
| US-20030229065-A1 | Transcription factor modulating compounds and methods of use thereof | RELA, ATF4, JUN | TNKS 2448/4885GABRP 3932/4885GABRD 2496/4885 |
| US-20050124678-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | TNKS 1140/4885GABRP 1579/4885GABRD 1267/4885 |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | TNKS 1222/4885GABRP 4389/4885GABRD 3099/4885 |
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | TNKS 1222/4885GABRP 4389/4885GABRD 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.